{"id":8995,"date":"2025-10-21T09:41:22","date_gmt":"2025-10-21T06:41:22","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8995"},"modified":"2025-10-21T09:41:22","modified_gmt":"2025-10-21T06:41:22","slug":"fda-endorses-endovascular-repair-for-ruptured-abdominal-aortic-aneurysm-raaa","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/fda-endorses-endovascular-repair-for-ruptured-abdominal-aortic-aneurysm-raaa\/","title":{"rendered":"FDA Endorses Endovascular Repair for Ruptured Abdominal Aortic Aneurysm (rAAA)"},"content":{"rendered":"<div>FDA Endorses Endovascular Repair for Ruptured Abdominal Aortic Aneurysm (rAAA)<\/div>\n<div><\/div>\n<div>Source: MassDevice &amp; Endovascular Today, October 13, 2025<\/div>\n<div><\/div>\n<div>Keynotes:<\/div>\n<div><span> 1. The U.S. FDA has approved a major labeling update recognizing endovascular aneurysm repair (EVAR) as a validated treatment for ruptured abdominal aortic aneurysm (rAAA) \u2014 a life-threatening vascular emergency.<\/span><\/div>\n<div><span> 2. Previously, EVAR was limited to elective aneurysm repair, while open surgery remained the only officially accepted treatment for ruptures.<\/span><\/div>\n<div><span> 3. Recent clinical evidence from large real-world registries confirms that EVAR offers comparable\u2014or superior\u2014outcomes to open repair in selected emergency cases, with lower mortality and quicker recovery.<\/span><\/div>\n<div><span> 4. Based on these data, regulators removed prior warnings and formally acknowledged the clinical safety and efficacy of endovascular repair for rAAA.<\/span><\/div>\n<div><\/div>\n<div>Clinical Overview (Diagnosis &amp; Management)<\/div>\n<div><span> \u2022 Typical presentation: Sudden abdominal or back pain, hypotension, and a pulsatile abdominal mass.<\/span><\/div>\n<div><span> \u2022 Diagnosis: Rapid CT angiography is the gold standard to confirm rupture and assess anatomical suitability for EVAR.<\/span><\/div>\n<div><span> \u2022 Initial management: Aggressive resuscitation with permissive hypotension, blood transfusion as needed, and immediate vascular consultation.<\/span><\/div>\n<div><span> \u2022 Treatment pathway:<\/span><\/div>\n<div><span> \u2022 EVAR preferred if patient anatomy and hemodynamics allow rapid access.<\/span><\/div>\n<div><span> \u2022 Open surgical repair reserved for unsuitable anatomy or unstable patients.<\/span><\/div>\n<div><span> \u2022 Post-repair monitoring: Intensive hemodynamic observation and serial imaging to detect endoleaks or graft complications.<\/span><\/div>\n<div><\/div>\n<div><span> 5. This FDA decision represents a paradigm shift in vascular care, making endovascular repair an officially recognized first-line option for ruptured aneurysm management.<\/span><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/evtoday.com\/news\/medtronics-endurant-stent-graft-systems-raaa-labeling-updated-by-fda?c4src=home\">https:\/\/evtoday.com\/news\/medtronics-endurant-stent-graft-systems-raaa-labeling-updated-by-fda?c4src=home<\/a><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FDA Endorses Endovascular Repair for Ruptured Abdominal Aortic Aneurysm (rAAA) Source: MassDevice &amp; Endovascular Today, October 13, 2025 Keynotes: 1. The U.S. FDA has approved a major labeling update recognizing endovascular aneurysm repair (EVAR) as a validated treatment for ruptured abdominal aortic aneurysm (rAAA) \u2014 a life-threatening vascular emergency. 2. Previously, EVAR was limited to [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8995","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8995","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8995"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8995\/revisions"}],"predecessor-version":[{"id":8996,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8995\/revisions\/8996"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8995"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8995"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}